The financing round was led by Vitruvian Partners with participation from the Amazon Alexa Fund, XTX Ventures and the Northern Powerhouse Investment Fund.
"I am delighted to announce our latest fundraising round led by Vitruvian Partners. Vitruvian’s experience supporting high-growth and innovative technology companies globally will be invaluable as we continue to scale up our capabilities and operations. Given the evolving threat landscape and the increasingly sophisticated technology being used by adversarial actors, this investment will help us continue to stay at the forefront of the fight against misinformation, funding further research and development of end-to-end technology solutions that really break down and combat information threats."
The seed round was co-led by Fin Capital and 1818 Ventures to accelerate the rollout of its buy now, pay later service.
"Accessing funds for businesses can be a painful, complex and time consuming experience, but we’re here to fix that. Our subscriptions offer clients access to easy, fast and affordable funding to spread their services into manageable payments. We’re helping businesses increase their liquidity and stretch their cash flow further and for longer."
The seed round was led by Parkwalk Advisors to support team expansion and product development.
"We are looking to interrupt a marketplace dominated by technologies reliant solely on sound, vision and increasingly, touch. Our sense of smell has the power to evoke long-forgotten memories, bring food to life, calm us down and enrich our lives. We create smell technologies that can be used across a range of innovative contexts. From leading healthcare research to artistic and immersive experiences, our products offer a total digital command over scent and smell."
The seed round was led by Quantum Exponential Group and Evenlode Impact to support diagnostic imaging development.
"The closing of Siloton’s first round of investment represents a new chapter in the company’s history. We have a strong management team with world-leading technical know-how. This knowledge is complemented by the considerable expertise contained within our investor base; including clinical, sector, and commercial experts. We are all deeply excited to begin working together and building a compelling product for patients with age-related macular degeneration"
